Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.98B 3.68B 3.43B 6.46B 430B 6.58B 44.1B 17.12B 212B 17.09B 16.71B 740B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.11B 3.8B 3.54B 6.67B 444B 6.79B 45.54B 17.68B 219B 17.65B 17.26B 764B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
3 months+0.21%
6 months+1.76%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.78
Extreme 5.78
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
04-27Issuer sale

General Counsel

1,264,993 0.4029%
04-27Issuer sale

Director

398,261 0.1268%
04-27Issuer sale

Director

446,194 0.1421%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+152.88%+15.37% 4.55B
+2.00%+5.60%-1.06%+5.40% 47.18B
-2.77%+10.48%+409.05%+600.11% 39.82B
-0.03%+12.81%+22.61%-14.04% 32.25B
-1.73%+3.20%+17.72%+59.83% 31.68B
-3.29%+7.98%+14.01%+29.96% 24.59B
+1.15%+11.79% - - 16.57B
-0.96%+11.85%+68.73%+120.51% 15.12B
-0.58%+1.73%+12.18%+17.07% 13.69B
-1.74%+4.34%+100.68%+93.25% 13.1B
Average -0.77%+6.61%+88.53%+103.05% 23.85B
Weighted average by Cap. -0.74%+7.22%+95.02%+133.69%

Financials

2024 2025
Net sales 528M 462M 427M 398M 750M 49.95B 764M 5.12B 1.99B 24.65B 1.98B 1.94B 85.87B 634M 555M 512M 478M 901M 59.97B 917M 6.15B 2.39B 29.59B 2.38B 2.33B 103B
Net income -56.11M -49.11M -45.33M -42.29M -79.68M -5.3B -81.1M -544M -211M -2.62B -211M -206M -9.12B -27.11M -23.73M -21.9M -20.43M -38.5M -2.56B -39.19M -263M -102M -1.26B -102M -99.58M -4.41B
Net Debt 194M 170M 157M 146M 275M 18.31B 280M 1.88B 729M 9.04B 728M 711M 31.48B 149M 130M 120M 112M 211M 14.07B 215M 1.44B 560M 6.94B 559M 547M 24.19B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock